Brokerages expect La Jolla Pharmaceutical Company (NASDAQ:LJPC) to announce sales of $170,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for La Jolla Pharmaceutical Company’s earnings, with the lowest sales estimate coming in at $90,000.00 and the highest estimate coming in at $250,000.00. La Jolla Pharmaceutical Company posted sales of $250,000.00 in the same quarter last year, which would indicate a negative year over year growth rate of 32%. The company is scheduled to issue its next quarterly earnings results on Monday, August 14th.

According to Zacks, analysts expect that La Jolla Pharmaceutical Company will report full-year sales of $170,000.00 for the current fiscal year, with estimates ranging from $280,000.00 to $1.00 million. For the next financial year, analysts forecast that the business will report sales of $33.40 million per share, with estimates ranging from $24.40 million to $50.81 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow La Jolla Pharmaceutical Company.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last issued its earnings results on Thursday, April 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.34) by $0.08. La Jolla Pharmaceutical Company had a negative return on equity of 89.72% and a negative net margin of 12,692.37%.

A number of brokerages recently issued reports on LJPC. ValuEngine upgraded shares of La Jolla Pharmaceutical Company from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical Company from a “sell” rating to a “hold” rating in a research report on Wednesday, April 26th. Cowen and Company restated a “buy” rating and set a $55.00 target price on shares of La Jolla Pharmaceutical Company in a research report on Friday, April 28th. SunTrust Banks, Inc. restated a “buy” rating and set a $57.00 target price on shares of La Jolla Pharmaceutical Company in a research report on Monday, May 22nd. Finally, Chardan Capital set a $34.00 target price on shares of La Jolla Pharmaceutical Company and gave the stock a “buy” rating in a research report on Monday, May 22nd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. La Jolla Pharmaceutical Company currently has a consensus rating of “Buy” and an average price target of $43.17.

La Jolla Pharmaceutical Company (LJPC) traded up 1.48% during mid-day trading on Friday, hitting $32.88. 152,196 shares of the stock traded hands. The stock’s 50 day moving average is $29.29 and its 200-day moving average is $26.14. La Jolla Pharmaceutical Company has a 12 month low of $14.63 and a 12 month high of $39.28. The company’s market cap is $727.40 million.

Several institutional investors have recently modified their holdings of LJPC. SG Americas Securities LLC acquired a new position in shares of La Jolla Pharmaceutical Company during the first quarter worth approximately $195,000. Teza Capital Management LLC acquired a new position in shares of La Jolla Pharmaceutical Company during the first quarter worth approximately $204,000. RidgeWorth Capital Management LLC acquired a new position in shares of La Jolla Pharmaceutical Company during the first quarter worth approximately $227,000. American International Group Inc. increased its position in shares of La Jolla Pharmaceutical Company by 7.1% in the first quarter. American International Group Inc. now owns 8,571 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 568 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of La Jolla Pharmaceutical Company during the first quarter worth approximately $271,000.

TRADEMARK VIOLATION NOTICE: “La Jolla Pharmaceutical Company (LJPC) Expected to Post Quarterly Sales of $170,000.00” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/16/la-jolla-pharmaceutical-company-ljpc-expected-to-post-quarterly-sales-of-170000-00.html.

La Jolla Pharmaceutical Company Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Get a free copy of the Zacks research report on La Jolla Pharmaceutical Company (LJPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.